NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

NCT06393387

CompletedN/A

Sponsor: Midway Specialty Care Center

Conditions: Hiv, HIV-1-infection, HIV Infections

Interventions: DTG/3TC versus BIC/F/TAF

Countries: United States

This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adults, aged 18 years and older;
* Diagnosis of HIV-1;
* Have a history of ART consisting of DTG/3TC or BIC/F/TAF, initiated from May 1, 2019 through January 28, 2023;
* Have at least 48 weeks of clinical follow up after initiation of DTG/3TC or BIC/F/TAF; clinical follow-up can include time post-discontinuation of either index regimen;
* Complete data, for HIV-1 RNA viral load at all study time points, including baseline, through 24 weeks and through 48 weeks;
* Received care from a physician, nurse practitioner or physician assistant at the organization

Exclusion Criteria:

* Index regimen is BIC/F/TAF and has a history of ART consisting of DTG+3TC or DTG/3TC;
* Index regimen is DTG/3TC and has a history of ART consisting of BIC/F/TAF

Locations (1)

West Palm Beach, Florida, United States